-
ALSO READ
Pfizer Covid-19 vaccine booster dose plan sparks controversy in US
Pfizer's Covid-19 vaccine may cost less than $10 a dose in India
Canada authorises Pfizer coronavirus vaccine for age 12 and older
Our vaccine highly effective on Covid-19 variant prevalent in India: Pfizer
UK approves Pfizer-BioNtech vaccine for use in 12- to 15-year-olds
-
Drug firm Pfizer Ltd on Wednesday reported an 8.81 per cent rise in net profit to Rs 142.95 crore for the quarter ended September 30, 2021.
The company had posted a net profit of Rs 131.37 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a filing to the BSE.
Revenue from operations stood at Rs 636.26 crore for the quarter under consideration, as against Rs 595.41 crore a year ago, it added.
"During the quarter the company has entered into a business transfer agreement with Mylan Pharmaceuticals Pvt Ltd to transfer certain primarily off-patented and generic established medicines business (Upjohn Business) as a going concern for a consideration of Rs 180.48 crore," Pfizer Ltd said.
Completion of transaction is subject to fulfilment of certain conditions as set out in the agreement, it added.
The Upjohn business comprises six brands -- Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin.
Revenue for the Upjohn business for the quarter ended September 2021 is Rs 21.1 crore, the filing said.
Shares of Pfizer Ltd closed at Rs 5,028.35 on BSE, down 1 per cent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU